James J Urbanic1, Xiaofei Wang2, Jeffrey A Bogart3, Thomas E Stinchcombe4, Lydia Hodgson2, Steven E Schild5, Lyudmila Bazhenova6, Olwen Hahn7, Ravi Salgia8, Everett E Vokes9. 1. Department of Radiation Medicine and Applied Sciences, University of California at San Diego, Moores Cancer Center, La Jolla, California. Electronic address: jurbanic@ucsd.edu. 2. Alliance Statistics and Data Center, Duke University, Durham, North Carolina. 3. Department of Radiation Oncology, State University of New York Upstate Medical University, Syracuse, New York. 4. Division of Hematology Oncology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina. 5. Department of Radiation Oncology, Mayo Clinic, Phoenix, Arizona. 6. Division of Hematology Oncology, University of California at San Diego, Moores Cancer Center, La Jolla, California. 7. Division of Hematology Oncology, Alliance Protocol Office, University of Chicago, Chicago, Illinois. 8. Division of Hematology Oncology, University of Chicago Comprehensive Cancer Center, Chicago, Illinois. 9. Department of Medicine, University of Chicago Comprehensive Cancer Center, Chicago, Illinois.
Abstract
PURPOSE: To investigate the safety of accelerated hypofractionated radiation therapy (AHRT) with concurrent chemotherapy (CT) for inoperable stage III non-small cell lung cancer (NSCLC). PATIENTS AND METHODS: The primary objectives were to define the maximally tolerable course of accelerated radiation therapy and to describe toxicities of therapy. Total radiation therapy remained at 60 Gy. The number of once-daily fractions in each successive cohort was reduced as follows: cohort 1, 60 Gy in 27 fractions; cohort 2, 60 Gy in 24 fractions; cohort 3, 60 Gy in 22 fractions; and cohort 4, 60 Gy in 20 fractions. Concurrent treatment consisted of weekly carboplatin area under the curve (AUC) 2 and paclitaxel 45 mg/m2. Consolidation treatment consisted of carboplatin AUC 6 and paclitaxel 200 mg/m2 every weeks × 2 cycles. Maximum tolerated dose: Of 6 patients/cohort, ≤2 patients experienced grade ≥3 toxicity, and ≤1 patient experienced grade ≥4 toxicity. RESULTS: 22 patients were accrued; of those, 21 patients were evaluable between July 2012 and May 2014. Grade 5 toxicity occurred in 3 patients: 1 patient in cohort 2 (hemoptysis), 2 patients in cohort 3 (hemoptysis, pneumonitis). The maximum tolerated dose (MTD) was defined by cohort 2 (60 Gy in 2.5 Gy/fraction). Time to grade 5 toxicity was 9 months, 6 months, and 9 months after the start of treatment. The median follow-up time was 23.0 months (range, 7.6-30.6 months) in living patients, the median overall survival was 19.3 months (95% confidence interval [CI] 9.3-34.0 months), and the median progression-free survival was 12.2 months (95% CI 6.1-22.5 months). CONCLUSIONS: Only modest hypofractionation was achievable as a result of long-term toxicities. Nevertheless, the MTD of 60 Gy given at 2.5 Gy/fraction allows completion of RT in 20% fewer treatments than conventional therapy. Further investigation of AHRT may help to better define the therapeutic index.
PURPOSE: To investigate the safety of accelerated hypofractionated radiation therapy (AHRT) with concurrent chemotherapy (CT) for inoperable stage III non-small cell lung cancer (NSCLC). PATIENTS AND METHODS: The primary objectives were to define the maximally tolerable course of accelerated radiation therapy and to describe toxicities of therapy. Total radiation therapy remained at 60 Gy. The number of once-daily fractions in each successive cohort was reduced as follows: cohort 1, 60 Gy in 27 fractions; cohort 2, 60 Gy in 24 fractions; cohort 3, 60 Gy in 22 fractions; and cohort 4, 60 Gy in 20 fractions. Concurrent treatment consisted of weekly carboplatin area under the curve (AUC) 2 and paclitaxel 45 mg/m2. Consolidation treatment consisted of carboplatin AUC 6 and paclitaxel 200 mg/m2 every weeks × 2 cycles. Maximum tolerated dose: Of 6 patients/cohort, ≤2 patients experienced grade ≥3 toxicity, and ≤1 patient experienced grade ≥4 toxicity. RESULTS: 22 patients were accrued; of those, 21 patients were evaluable between July 2012 and May 2014. Grade 5 toxicity occurred in 3 patients: 1 patient in cohort 2 (hemoptysis), 2 patients in cohort 3 (hemoptysis, pneumonitis). The maximum tolerated dose (MTD) was defined by cohort 2 (60 Gy in 2.5 Gy/fraction). Time to grade 5 toxicity was 9 months, 6 months, and 9 months after the start of treatment. The median follow-up time was 23.0 months (range, 7.6-30.6 months) in living patients, the median overall survival was 19.3 months (95% confidence interval [CI] 9.3-34.0 months), and the median progression-free survival was 12.2 months (95% CI 6.1-22.5 months). CONCLUSIONS: Only modest hypofractionation was achievable as a result of long-term toxicities. Nevertheless, the MTD of 60 Gy given at 2.5 Gy/fraction allows completion of RT in 20% fewer treatments than conventional therapy. Further investigation of AHRT may help to better define the therapeutic index.
Authors: Kwan Ho Cho; Sung Ja Ahn; Hong Ryull Pyo; Kyu-Sik Kim; Young-Chul Kim; Sung Ho Moon; Ji-Youn Han; Heung Tae Kim; Woong Sub Koom; Jin Soo Lee Journal: Int J Radiat Oncol Biol Phys Date: 2008-12-29 Impact factor: 7.038
Authors: Nitin Ohri; Xinglei Shen; Adam P Dicker; Laura A Doyle; Amy S Harrison; Timothy N Showalter Journal: J Natl Cancer Inst Date: 2013-03-06 Impact factor: 13.506
Authors: M A Socinski; J G Rosenman; J Halle; M J Schell; Y Lin; S Russo; M P Rivera; J Clark; S Limentani; R Fraser; W Mitchell; F C Detterbeck Journal: Cancer Date: 2001-09-01 Impact factor: 6.860
Authors: Jeffrey A Bogart; Lydia Hodgson; Stephen L Seagren; A William Blackstock; Xiaofei Wang; Robert Lenox; Andrew T Turrisi; John Reilly; Ajeet Gajra; Everett E Vokes; Mark R Green Journal: J Clin Oncol Date: 2009-11-23 Impact factor: 44.544
Authors: Donald M Cannon; Minesh P Mehta; Jarrod B Adkison; Deepak Khuntia; Anne M Traynor; Wolfgang A Tomé; Richard J Chappell; Ranjini Tolakanahalli; Pranshu Mohindra; Søren M Bentzen; George M Cannon Journal: J Clin Oncol Date: 2013-10-21 Impact factor: 44.544
Authors: Chris R Kelsey; Shiva Das; Lin Gu; Frank R Dunphy; Neal E Ready; Lawrence B Marks Journal: Int J Radiat Oncol Biol Phys Date: 2015-09-15 Impact factor: 7.038
Authors: Tawfik Giaddui; Wenzhou Chen; Jialu Yu; Liyong Lin; Charles B Simone; Lulin Yuan; Yutao U T Gong; Q Jackie Wu; Radhe Mohan; Xiaodong Zhang; Jaques B Bluett; Michael Gillin; Kevin Moore; Elizabeth O'Meara; Jennifer Presley; Jeffrey D Bradley; Zhongxing Liao; James Galvin; Ying Xiao Journal: Radiat Oncol Date: 2016-05-04 Impact factor: 3.481
Authors: Michelle Iocolano; Aaron T Wild; Margaret Hannum; Zhigang Zhang; Charles B Simone; Daphna Gelblum; Abraham J Wu; Andreas Rimner; Annemarie F Shepherd Journal: Acta Oncol Date: 2019-10-12 Impact factor: 4.089
Authors: Núria Rodríguez De Dios; Arturo Navarro-Martin; Cristina Cigarral; Rodolfo Chicas-Sett; Rafael García; Virginia Garcia; Jose Antonio Gonzalez; Susana Gonzalo; Mauricio Murcia-Mejía; Rogelio Robaina; Amalia Sotoca; Carmen Vallejo; German Valtueña; Felipe Couñago Journal: World J Clin Oncol Date: 2022-04-24
Authors: Jiahua Lyu; Tao Liu; Tao Li; Fang Li; Qifeng Wang; Jie Wang; Yongtao Han; Junchao Wang; Jun Zhang; Lin Peng; Jinyi Lang Journal: Cancer Med Date: 2019-05-22 Impact factor: 4.452
Authors: Bin Wang; Da Quan Wang; Mao Sheng Lin; Shi Pei Lu; Jun Zhang; Li Chen; Qi Wen Li; Zhang Kai Cheng; Fang Jie Liu; Jin Yu Guo; Hui Liu; Bo Qiu Journal: BMC Cancer Date: 2020-11-16 Impact factor: 4.430